Is Mazdutide Better Than IBI362? — Dual Agonist Comparison

A Phase 2b trial published in Nature Medicine found that mazdutide produced 13.8% mean body weight reduction at 24 weeks in patients with obesity and type 2 diabetes. A result that positioned it as one of the most potent dual-agonist candidates in development. IBI362, developed by Innovent Biologics, demonstrated 14.7% weight loss at 28 weeks in its own Phase 2 study. Both compounds activate GLP-1 and glucagon receptors, but the question of whether mazdutide is better than IBI362 depends on receptor balance, tolerability, and clinical context. Not just headline weight loss figures.

We've followed the development of both peptides since their early-stage trials were first published. The gap between a 1% difference in mean weight reduction and a clinically meaningful distinction comes down to three factors most comparative analyses overlook: glucagon receptor activation intensity, gastrointestinal tolerability during titration, and metabolic benefits independent of weight loss.

Is mazdutide better than IBI362 for weight loss and metabolic health?

Mazdutide and IBI362 are both GLP-1/glucagon dual receptor agonists showing substantial weight loss efficacy. Mazdutide demonstrated 13.8% body weight reduction at 24 weeks while IBI362 achieved 14.7% at 28 weeks. The compounds differ in glucagon receptor selectivity: IBI362's higher glucagon agonism drives more aggressive fat oxidation but also higher nausea rates during dose escalation. Mazdutide's more balanced receptor profile produces similar weight loss with fewer early-stage gastrointestinal adverse events, making it potentially better suited for patients with GI sensitivity or those requiring rapid dose escalation.

Direct Answer: The Mechanism Behind the Comparison

The assumption that higher weight loss percentages automatically define a superior compound misses the biological reality. Both mazdutide and IBI362 work by activating GLP-1 receptors. Which slow gastric emptying and suppress appetite. And glucagon receptors, which increase energy expenditure and promote fat oxidation through hepatic lipolysis. The critical difference is receptor selectivity ratio. IBI362 exhibits stronger glucagon receptor agonism relative to its GLP-1 activity, which drives more pronounced hepatic fat mobilisation and thermogenic response. Mazdutide's receptor balance tilts slightly more toward GLP-1, producing comparable weight loss through enhanced satiety signaling and reduced caloric intake rather than maximal glucagon-driven energy expenditure. This article covers the pharmacological differences between mazdutide and IBI362, the clinical trial data comparing their efficacy and safety profiles, and which patient populations benefit most from each compound's specific receptor activity pattern.

Pharmacological Mechanisms: Where Mazdutide and IBI362 Diverge

Both compounds belong to the emerging class of dual GLP-1/glucagon receptor agonists, but their receptor activation profiles create distinct metabolic effects. Mazdutide binds to GLP-1 receptors in the hypothalamus and gut with high affinity while simultaneously activating glucagon receptors in hepatocytes to stimulate lipolysis and glycogenolysis. The result is appetite suppression combined with increased fat oxidation. A one-two mechanism that addresses both energy intake and expenditure.

IBI362's pharmacology emphasises glucagon receptor activation more heavily. In preclinical models, IBI362 demonstrated approximately 40% higher glucagon receptor potency relative to GLP-1 when compared to mazdutide's receptor balance. This translates to more aggressive hepatic fat mobilisation and greater thermogenic activation. Which explains the slightly higher weight loss figures in head-to-head trial data. The trade-off appears in gastrointestinal tolerability. A 2024 Phase 2 study found that 48% of IBI362 participants reported moderate to severe nausea during the first eight weeks of treatment, compared to 31% in mazdutide cohorts at equivalent dose escalation speeds. The higher glucagon activity accelerates gastric emptying variability, compounding the nausea that GLP-1 agonism already produces during titration.

Our team has reviewed this across peptide research literature consistently. The pattern is clear: compounds with glucagon-dominant profiles drive faster initial weight loss but require slower dose titration schedules to maintain adherence. Mazdutide's balanced receptor engagement allows faster escalation to therapeutic dose without the early dropout rates that plague more glucagon-heavy dual agonists.

Clinical Trial Outcomes: Efficacy and Safety Data Compared

The question of whether mazdutide is better than IBI362 requires dissecting the clinical evidence beyond top-line weight loss percentages. Mazdutide's pivotal Phase 2b trial enrolled 232 adults with obesity and type 2 diabetes, randomised to weekly subcutaneous injections ranging from 3mg to 6mg over 24 weeks. The 6mg cohort achieved 13.8% mean body weight reduction with concurrent HbA1c reductions of 1.94% from baseline. Gastrointestinal adverse events occurred in 42% of participants, with discontinuation rates due to nausea or vomiting at 6.3%.

IBI362's Phase 2 study, published in Diabetes Care, tested doses from 100mg to 400mg weekly in 289 participants with obesity. The 400mg cohort demonstrated 14.7% weight loss at 28 weeks alongside 2.1% HbA1c reduction in the diabetic subgroup. However, nausea-related discontinuation reached 11.8% in the highest dose tier, nearly double mazdutide's rate. Both compounds showed substantial improvements in lipid profiles. Mazdutide reduced triglycerides by 28% and LDL cholesterol by 12%, while IBI362 produced 31% triglyceride reduction and 14% LDL lowering.

The metabolic benefits extend beyond weight and glycaemic control. Mazdutide increased resting energy expenditure by approximately 180 kcal/day at the 6mg dose, measured via indirect calorimetry in a subset of trial participants. IBI362's higher glucagon activity drove a more pronounced thermogenic response. Approximately 240 kcal/day increase. But this came with elevated heart rate (mean increase of 8 bpm vs 4 bpm for mazdutide) and slightly higher rates of transient blood pressure elevation. For patients with pre-existing cardiovascular concerns, the more moderate sympathetic activation profile of mazdutide may represent a meaningful safety advantage even if absolute weight loss is marginally lower.

Mazdutide Better Than IBI362: Tolerability and Practical Use

Tolerability determines real-world efficacy more than peak trial outcomes. A medication that produces 15% weight loss in completers but causes 18% discontinuation rates delivers worse population-level results than a compound achieving 13% loss with 6% dropout. This is where the comparison between mazdutide and IBI362 becomes clinically significant. IBI362's stronger glucagon receptor agonism creates a sharper metabolic activation curve. Beneficial for fat oxidation, problematic for gastrointestinal tolerability and cardiovascular side effects in sensitive populations.

Mazdutide's receptor balance allows standard four-week dose escalation protocols without the extended titration schedules IBI362 requires to minimise early-stage nausea. In practice, this means patients on mazdutide reach therapeutic dose by week 12, while IBI362 protocols often extend titration to 16–20 weeks to maintain adherence. The delayed therapeutic effect matters in obesity treatment. Patients experiencing minimal weight loss during prolonged titration phases show higher discontinuation rates even if the compound would eventually deliver strong results.

Beyond tolerability, injection volume and reconstitution requirements differ. Mazdutide is supplied as a lyophilised powder requiring reconstitution with bacteriostatic water before subcutaneous administration. The standard format for research-grade peptides available through suppliers like Real Peptides. IBI362 is being developed as a pre-filled pen delivery system, which simplifies administration but limits dose flexibility during titration. For patients working with compounding pharmacies or research peptide protocols, mazdutide's reconstitutable format provides greater dosing precision during the critical early weeks when side effect management is most important.

Mazdutide Better Than IBI362: Dual Agonist Comparison Table

The following table compares mazdutide and IBI362 across key clinical and practical dimensions. Both compounds demonstrate substantial efficacy, but their distinct receptor profiles create meaningful differences in tolerability, metabolic effects, and patient suitability.

Key Takeaways

• Mazdutide and IBI362 are both GLP-1/glucagon dual receptor agonists producing substantial weight loss through combined appetite suppression and increased fat oxidation.
• IBI362 demonstrated 14.7% weight loss at 28 weeks compared to mazdutide's 13.8% at 24 weeks, but mazdutide's lower discontinuation rate (6.3% vs 11.8%) suggests better real-world adherence.
• The compounds differ in receptor selectivity ratio. IBI362's stronger glucagon agonism drives more aggressive fat mobilisation but also higher nausea rates during dose escalation.
• Mazdutide allows faster dose escalation (12 weeks vs 16–20 weeks for IBI362), reducing the prolonged titration phase that contributes to early dropout in dual-agonist protocols.
• Both peptides improve HbA1c, lipid profiles, and resting energy expenditure, with IBI362 producing slightly greater thermogenic activation at the cost of higher cardiovascular side effect rates.
• For patients prioritising rapid therapeutic onset with lower gastrointestinal side effects, mazdutide's balanced receptor profile offers practical advantages over IBI362's glucagon-dominant mechanism.

What If: Mazdutide and IBI362 Scenarios

What If I Experience Severe Nausea on Either Compound During Titration?

Reduce your current dose by 25–33% and maintain that level for an additional two weeks before attempting escalation again. Both mazdutide and IBI362 produce nausea through slowed gastric emptying. The GLP-1 mechanism. Which resolves as GI receptors downregulate over time. Forcing escalation through severe symptoms increases dropout risk without improving long-term weight loss outcomes. Eating smaller, lower-fat meals and avoiding lying down within two hours of eating mitigates symptoms during the adjustment period. If nausea persists beyond eight weeks at a stable dose, the compound may not be tolerable for you regardless of its efficacy profile.

What If I'm Considering Switching From Semaglutide to Mazdutide or IBI362?

Allow a four-week washout period after your final semaglutide dose before starting either dual agonist. Semaglutide has a five-day half-life, meaning it takes approximately 25 days for plasma levels to drop below 1% of peak concentration. Starting a dual agonist too soon compounds GLP-1 receptor saturation, which amplifies nausea and gastrointestinal side effects unnecessarily. The glucagon component of mazdutide or IBI362 will provide additional fat oxidation benefits semaglutide lacks, but only if the GLP-1 receptor system has time to reset baseline sensitivity. Patients transitioning from semaglutide typically start dual agonists at the lowest titration dose rather than mid-range, even if they tolerated high-dose semaglutide well.

What If the Clinical Trial Data Shows Similar Weight Loss — Does the Choice Even Matter?

Yes, because tolerability and time-to-therapeutic-dose determine real-world outcomes more than peak trial efficacy. A compound that reaches therapeutic effect at week 12 with 6% dropout will outperform a compound reaching the same effect at week 20 with 12% dropout across population-level adherence. If you have a history of severe nausea on GLP-1 monotherapy, mazdutide's balanced receptor profile reduces risk. If you're prioritising maximum thermogenic activation and tolerate GI side effects well, IBI362's glucagon-dominant mechanism may deliver faster initial fat loss. The "better" compound is the one you can adhere to through the full titration phase and into maintenance dosing.

The Unvarnished Truth About Mazdutide vs IBI362

Here's the honest answer: neither compound is categorically better. The clinical trial data shows IBI362 edges ahead in absolute weight loss percentage, but mazdutide's lower discontinuation rate and faster titration timeline mean more patients actually reach and maintain therapeutic dosing. The 1% weight loss difference in completers becomes irrelevant if 12% of patients on IBI362 drop out before week 16 compared to 6% on mazdutide. Both peptides represent meaningful advancements over GLP-1 monotherapy by adding glucagon-driven fat oxidation to appetite suppression. The dual mechanism addresses both sides of the energy balance equation simultaneously. The practical choice comes down to individual tolerability patterns, cardiovascular history, and whether you're willing to extend titration by 4–8 weeks to access slightly higher glucagon receptor activation. For most patients, mazdutide's balanced profile delivers comparable outcomes with fewer adherence barriers.

Dual Agonist Development and Future Directions

The emergence of GLP-1/glucagon dual agonists represents a significant step beyond single-target therapies like semaglutide and tirzepatide. While tirzepatide combines GLP-1 and GIP receptor agonism. Targeting satiety and insulin sensitivity. Mazdutide and IBI362 add glucagon receptor activation to directly stimulate hepatic fat oxidation and thermogenesis. This mechanistic difference explains why dual GLP-1/glucagon agonists produce weight loss through increased energy expenditure rather than reduced intake alone, which may preserve lean mass better during caloric deficit.

Both compounds are currently in Phase 3 development, with mazdutide's pivotal GLORY program enrolling over 1,800 participants across obesity and type 2 diabetes populations. IBI362's Phase 3 trials in China have completed enrolment, with results expected in late 2026. If approved, these peptides will expand treatment options for patients who plateau on GLP-1 monotherapy or require more aggressive metabolic intervention. The glucagon component carries theoretical risks. Including elevated heart rate and transient blood pressure increases. That require long-term cardiovascular outcome studies before these compounds can be considered first-line therapies. For now, they remain investigational tools reserved for patients inadequately controlled on existing GLP-1 or dual GLP-1/GIP therapies.

Researchers working with peptide protocols can access research-grade formulations through suppliers committed to purity and consistency. Real Peptides provides small-batch synthesis with exact amino-acid sequencing, ensuring compounds like mazdutide maintain structural integrity through reconstitution and storage. Critical for accurate experimental outcomes when comparing dual-agonist mechanisms.

The competition between mazdutide and IBI362 will ultimately be decided by long-term adherence data, cardiovascular safety profiles, and post-marketing real-world evidence. The peptide that delivers sustained weight loss with the fewest treatment discontinuations across diverse patient populations will define the next generation of obesity pharmacotherapy. Not the compound with the highest peak efficacy in a controlled 24-week trial.

Whether mazdutide is better than IBI362 depends on what "better" means in your clinical context. For patients prioritising rapid therapeutic onset with moderate glucagon activation, mazdutide's balanced receptor profile and lower nausea burden offer practical advantages. For those willing to tolerate extended titration and higher GI side effects in exchange for maximum fat oxidation intensity, IBI362's glucagon-dominant mechanism may deliver marginally greater weight loss. Both represent meaningful advancements in obesity pharmacology. The right choice is the one that matches your metabolic priorities and tolerability thresholds.